Deutsche Bank initiated coverage of Xenon Pharmaceuticals (XENE) with a Buy rating and $67 price target
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on XENE:
- Positive Long-Term Outlook for Xenon Pharmaceuticals Amid Anticipated Epilepsy Data Event
- Xenon Pharmaceuticals’ CCO Departure and Consultancy Role
- Xenon Pharmaceuticals Sets Sights on Key 2025 Milestones
- Xenon Pharmaceuticals outlines key corporate milestone opportunities for 2025
- Xenon to Showcase Innovations at J.P. Morgan Healthcare Conference